Comparison 2. Any antiglucocorticoid versus placebo as adjunct to atypical antipsychotic treatment (data only for DHEA).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mental state: 1. General ‐ average endpoint score (PANSS total, high score = poor)	1	40	Mean Difference (IV, Fixed, 95% CI)	‐1.70 [‐10.78, 7.38]
2 Mental state: 2a. Specific ‐ positive and negative symptoms ‐ average endpoint score (PANSS subscales, high score = poor)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 negative subscale	1	40	Mean Difference (IV, Fixed, 95% CI)	0.70 [‐2.63, 4.03]
2.2 positive subscale	1	40	Mean Difference (IV, Fixed, 95% CI)	‐1.0 [‐3.20, 1.20]
3 Mental state: 2b. Specific ‐ negative symptoms ‐ average endpoint scores (SANS negative subscale, high score = poor, data skewed)			Other data	No numeric data
4 Mental state: 2c. Specific ‐ depression ‐ average endpoint scores (CDSS total, high score = poor, skewed data)			Other data	No numeric data
5 Global state: 1. Leaving the study early	1	40	Risk Ratio (M‐H, Fixed, 95% CI)	0.8 [0.25, 2.55]
6 Adverse effects: extrapyramidal symptoms ‐ average endpoint scores parkinsonism (SAS total, high scores = poor)	1	40	Mean Difference (IV, Fixed, 95% CI)	0.0 [‐0.88, 0.88]
7 Adverse effects: weight gain ‐ average body weight endpoint	1	40	Mean Difference (IV, Fixed, 95% CI)	5.20 [‐4.51, 14.91]